发布时间：2026-05-20 09:55 Ustekinumab BS 45 mg Syringe for S.C. Injection「NIPRO」 is now available in Japan, after its listing under the National Health Insurance (NHI) Drug Price Standard
Marks first launch in Japan through partnership with NIPRO CORPORATION
Samsung Bioepis continues to expand its global presence, widening access to life-enhancing treatments for patients with chronic autoimmune conditions
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced the launch of Ustekinumab BS 45 mg Syringe for S.C. Injection「 NIPRO」, a biosimilar referencing Stelara1 (ustekinumab), marking its first product launch in Japan under partnership with NIPRO CORPORATION (hereafter “NIPRO”). The launch follows the Official Gazette announcement on May 19 regarding the product’s listing under the National Health Insurance (NHI) Drug Price Standard, which became effective today.




"We are thrilled to announce the launch of our first bi
=*=*=*=*=*=
当前为第1/4页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页